Literature DB >> 21590266

Phenotypic spectrum of 80 Greek patients referred as Noonan syndrome and PTPN11 mutation analysis: the value of initial clinical assessment.

Anna Papadopoulou1, Michalis Issakidis, Evangelia Gole, Konstantina Kosma, Helen Fryssira, Andreas Fretzayas, Polyxeni Nicolaidou, Sophia Kitsiou-Tzeli.   

Abstract

Noonan syndrome (NS) is a common multiple congenital anomaly entity, the diagnosis of which, on clinical grounds, is based on a comprehensive scoring system in order to select patients for molecular confirmation. Our aim was to evaluate the phenotypic characteristics in the light of PTPN11 mutations. The study revealed 80 patients who were referred with initial indication of NS or Noonan-like syndrome (NLS) and further assessed by a clinical geneticist; 60/80 index patients, mean age 5.9 ± 5.3 years, fulfilled the NS criteria. Molecular analysis of PTPN11 gene (exons and their flanking regions) of the total population revealed mutations in 17/80 patients, all belonging in the group of the patients screened with the scoring system. All mutations were heterozygous missense changes, mostly clustering in exon 3 (8/17), followed by exons 13 (3/17), 8 (2/17), 7 (2/17), 2 (1/17) and 4 (1/17). We conclude that (a) most of our clinically diagnosed NS cases were sporadic (b) PTPN11 analysis should be limited to those fulfilling the relevant NS criteria (c) Cardiovascular evaluation should comprise all NS patients, while pulmonary stenosis, short stature, and thorax deformities prevailed among those with PTPN11 mutations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21590266     DOI: 10.1007/s00431-011-1487-5

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  52 in total

Review 1.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.

Authors:  Benjamin G Neel; Haihua Gu; Lily Pao
Journal:  Trends Biochem Sci       Date:  2003-06       Impact factor: 13.807

Review 2.  Juvenile myelomonocytic leukemia and Noonan syndrome.

Authors:  K Choong; M H Freedman; D Chitayat; E N Kelly; G Taylor; A Zipursky
Journal:  J Pediatr Hematol Oncol       Date:  1999 Nov-Dec       Impact factor: 1.289

3.  The Ullrich-Noonan syndrome (Turner phenotype).

Authors:  J J Nora; A H Nora; A K Sinha; R D Spangler; H A Lubs
Journal:  Am J Dis Child       Date:  1974-01

4.  Clinical and molecular studies in a large Dutch family with Noonan syndrome.

Authors:  I van der Burgt; E Berends; E Lommen; S van Beersum; B Hamel; E Mariman
Journal:  Am J Med Genet       Date:  1994-11-01

5.  Noonan syndrome: the changing phenotype.

Authors:  J E Allanson; J G Hall; H E Hughes; M Preus; R D Witt
Journal:  Am J Med Genet       Date:  1985-07

6.  The face of Noonan syndrome: Does phenotype predict genotype.

Authors:  Judith E Allanson; Axel Bohring; Helmuth-Guenther Dörr; Andreas Dufke; Gabrielle Gillessen-Kaesbach; Denise Horn; Rainer König; Christian P Kratz; Kerstin Kutsche; Silke Pauli; Salmo Raskin; Anita Rauch; Anne Turner; Dagmar Wieczorek; Martin Zenker
Journal:  Am J Med Genet A       Date:  2010-08       Impact factor: 2.802

7.  Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation.

Authors:  Tomoko Kobayashi; Yoko Aoki; Tetsuya Niihori; Hélène Cavé; Alain Verloes; Nobuhiko Okamoto; Hiroshi Kawame; Ikuma Fujiwara; Fumio Takada; Takako Ohata; Satoru Sakazume; Tatsuya Ando; Noriko Nakagawa; Pablo Lapunzina; Antonio G Meneses; Gabriele Gillessen-Kaesbach; Dagmar Wieczorek; Kenji Kurosawa; Seiji Mizuno; Hirofumi Ohashi; Albert David; Nicole Philip; Afag Guliyeva; Yoko Narumi; Shigeo Kure; Shigeru Tsuchiya; Yoichi Matsubara
Journal:  Hum Mutat       Date:  2010-03       Impact factor: 4.878

8.  Rhabdomyosarcoma in a patient with Noonan syndrome phenotype and review of the literature.

Authors:  Maria Moschovi; Vassiliki Touliatou; Touliatou Vassiliki; Anna Papadopoulou; Papadopoulou Anna; Maria-Alexandra Mayakou; Mayakou Maria-Alexandra; Polyxeni Nikolaidou-Karpathiou; Nikolaidou-Karpathiou Polyxeni; Sophia Kitsiou-Tzeli; Kitsiou-Tzeli Sophia
Journal:  J Pediatr Hematol Oncol       Date:  2007-05       Impact factor: 1.289

9.  Coinheritance of Noonan syndrome and Becker muscular dystrophy.

Authors:  Argirios Dinopoulos; Anna Papadopoulou; Panagiota Manta; Kiki Kekou; Tassos Kanelopoulos; Andreas Fretzayas; Sofia Kitsiou
Journal:  Neuromuscul Disord       Date:  2009-10-28       Impact factor: 4.296

10.  Germline KRAS mutations cause Noonan syndrome.

Authors:  Suzanne Schubbert; Martin Zenker; Sara L Rowe; Silke Böll; Cornelia Klein; Gideon Bollag; Ineke van der Burgt; Luciana Musante; Vera Kalscheuer; Lars-Erik Wehner; Hoa Nguyen; Brian West; Kam Y J Zhang; Erik Sistermans; Anita Rauch; Charlotte M Niemeyer; Kevin Shannon; Christian P Kratz
Journal:  Nat Genet       Date:  2006-02-12       Impact factor: 38.330

View more
  7 in total

1.  Molecular and clinical profile of patients referred as Noonan or Noonan-like syndrome in Greece: a cohort of 86 patients.

Authors:  George Papadopoulos; Anna Papadopoulou; Konstantina Kosma; Anastasios Papadimitriou; Vassiliki Papaevangelou; Christina Kanaka-Gantenbein; Evangelia Bountouvi; Sophia Kitsiou-Tzeli
Journal:  Eur J Pediatr       Date:  2022-07-29       Impact factor: 3.860

2.  Mutation Spectrum and Phenotypic Features in Noonan Syndrome with PTPN11 Mutations: Definition of Two Novel Mutations.

Authors:  Tahir Atik; Ayca Aykut; Filiz Hazan; Huseyin Onay; Damla Goksen; Sukran Darcan; Ajlan Tukun; Ferda Ozkinay
Journal:  Indian J Pediatr       Date:  2016-01-28       Impact factor: 1.967

3.  Association between phosphatase related gene variants and coronary artery disease: case-control study and meta-analysis.

Authors:  Xia Han; Lijun Zhang; Zhiqiang Zhang; Zengtang Zhang; Jianchun Wang; Jun Yang; Jiamin Niu
Journal:  Int J Mol Sci       Date:  2014-08-13       Impact factor: 5.923

4.  Co-occurrence of hypertrophic cardiomyopathy and juvenile myelomonocytic leukemia in a neonate with Noonan syndrome, leading to premature death.

Authors:  Akihiro Tamura; Suguru Uemura; Kousaku Matsubara; Eru Kozuki; Toshikatsu Tanaka; Nanako Nino; Takehito Yokoi; Atsuro Saito; Toshiaki Ishida; Daiichiro Hasegawa; Ikumi Umeki; Tetsuya Niihori; Yozo Nakazawa; Kenichi Koike; Yoko Aoki; Yoshiyuki Kosaka
Journal:  Clin Case Rep       Date:  2018-05-08

5.  The spectrum of genetic variants and phenotypic features of Southeast Asian patients with Noonan syndrome.

Authors:  Ai-Ling Koh; Ee-Shien Tan; Maggie S Brett; Angeline H M Lai; Saumya Shekhar Jamuar; Ivy Ng; Ene-Choo Tan
Journal:  Mol Genet Genomic Med       Date:  2019-02-19       Impact factor: 2.183

6.  Molecular and clinical studies in 107 Noonan syndrome affected individuals with PTPN11 mutations.

Authors:  Jeevana Praharsha Athota; Meenakshi Bhat; Sheela Nampoothiri; Kalpana Gowrishankar; Sanjeeva Ghanti Narayanachar; Vinuth Puttamallesh; Mohammed Oomer Farooque; Swathi Shetty
Journal:  BMC Med Genet       Date:  2020-03-12       Impact factor: 2.103

7.  An Association of PTPN11 and SHOX Mutations in a Male Presenting With Syndromic Growth Failure.

Authors:  Emanuela Savarese; Benedetta Di Felice; Francesco Miconi; Gabriele Cabiati; Federica Celi; Francesco Crescenzi; Nicola Principi; Susanna Esposito
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-20       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.